Ilmarinen Mutual Pension Insurance Co Has $12.06 Million Position in Elevance Health, Inc. $ELV

Ilmarinen Mutual Pension Insurance Co reduced its position in shares of Elevance Health, Inc. (NYSE:ELV) by 26.2% in the 4th quarter, Holdings Channel reports. The institutional investor owned 34,400 shares of the company’s stock after selling 12,200 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Elevance Health were worth $12,059,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of ELV. Artisan Partners Limited Partnership boosted its position in shares of Elevance Health by 24.5% during the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after buying an additional 901,626 shares during the period. First Eagle Investment Management LLC boosted its position in shares of Elevance Health by 25.0% during the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after buying an additional 798,457 shares during the period. Brave Warrior Advisors LLC boosted its position in shares of Elevance Health by 65.3% during the third quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock worth $592,603,000 after buying an additional 724,349 shares during the period. Baupost Group LLC MA boosted its position in shares of Elevance Health by 114.1% during the third quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company’s stock worth $426,195,000 after buying an additional 703,000 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC boosted its position in shares of Elevance Health by 44.2% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company’s stock worth $660,935,000 after buying an additional 627,038 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Bank of America raised Elevance Health from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $405.00 to $435.00 in a research report on Wednesday, April 29th. Truist Financial reduced their price objective on Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Barclays upped their price objective on Elevance Health from $408.00 to $480.00 and gave the stock an “overweight” rating in a research report on Tuesday. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Finally, Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and increased their price target for the company from $363.00 to $498.00 in a research report on Wednesday, May 20th. Fourteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $403.11.

Elevance Health Stock Performance

ELV opened at $392.47 on Friday. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $408.00. The stock has a market cap of $85.23 billion, a price-to-earnings ratio of 16.69, a PEG ratio of 2.21 and a beta of 0.66. The business has a 50 day moving average of $341.76 and a 200-day moving average of $338.51. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same period last year, the firm posted $11.97 earnings per share. The business’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts expect that Elevance Health, Inc. will post 26.93 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is presently 29.26%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.